By Adria Calatayud

Hikma Pharmaceuticals PLC said Thursday that talks have ceased over a potential acquisition of GlaxoSmithKline PLC's pharmaceutical and consumer businesses in Egypt and pharmaceutical business in Tunisia.

FTSE 100 pharmaceutical company Hikma said it won't be launching a mandatory tender offer process to acquire shares in GlaxoSmithKline SAE Egypt.

Hikma in January said that it had entered into a preliminary agreement with GSK's Egyptian subsidiary.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

March 11, 2021 09:02 ET (14:02 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Hikma Pharmaceuticals (PK) 차트를 더 보려면 여기를 클릭.
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Hikma Pharmaceuticals (PK) 차트를 더 보려면 여기를 클릭.